Finasteride: What the Evidence Says, and What to Ask About

Finasteride is one of the few hair-loss treatments with a genuine evidence base, which is exactly why it deserves to be discussed carefully rather than enthusiastically. Online pharmacies sell it with a few clicks and a cheerful tone; the message boards that follow people who've taken it are a good deal less cheerful. The truth sits between those two, and an honest account has to hold both halves at once: the drug works, and the questions some people raise about it are real and not yet fully settled.

This is a prescription-only medicine for a reason. The aim here isn't to talk anyone into it or out of it — it's to explain what the evidence shows, and what a sensible person would want to discuss with the clinician who'd be responsible for prescribing it.

What finasteride actually does

Pattern hair loss in men is driven, in genetically susceptible follicles, by dihydrotestosterone (DHT) — a potent androgen made from testosterone by an enzyme called 5-alpha-reductase. DHT is what gradually shrinks affected follicles, cycle by cycle, until they produce only fine, short hairs. Finasteride blocks one form of that enzyme, lowering DHT levels substantially. Less DHT means less of the signal that drives miniaturisation.

It's worth being clear about what kind of intervention this is. Finasteride doesn't regrow a bald scalp from scratch; it works mainly by slowing or halting the ongoing loss, and in many men producing some partial regrowth of miniaturised follicles. It treats the process, not the history — which is why its effect depends on continued use, and why hair maintained on treatment is gradually lost again if the drug is stopped.

How well it works

The efficacy data are reasonably good and consistent. In trials of men with pattern hair loss, daily finasteride increased hair counts and slowed progression compared with placebo over one to two years, with most men either maintaining their hair or seeing modest improvement. It is, on the evidence, one of the more effective medical treatments available for male pattern loss.

Two honest caveats sit alongside that. First, the benefit is maintenance-dependent and develops slowly — months, not weeks — so judging it requires patience. Second, "works in trials" describes an average across many men; the response in any individual varies, and no one can promise a particular outcome in advance.

The side-effect debate, fairly stated

This is where the conversation gets harder, and where it's important to be neither dismissive nor alarmist.

A proportion of men in trials reported sexual side effects — reduced libido, erectile difficulties, problems with ejaculation. In the controlled studies these were uncommon, occurred in a minority, and in most cases resolved either on continuing the drug or after stopping it. That is the reassuring framing, and it is honestly held by many clinicians.

The harder part is what's come to be called post-finasteride syndrome: reports from some men of sexual, mood-related or cognitive symptoms that they describe as persisting after stopping the medicine. This is genuinely contested territory. The reports are real in the sense that people are describing real distress; what remains uncertain is how often such persistence truly occurs, what mechanism might underlie it, and how to separate a drug effect from other contributors. The evidence is not strong enough to confirm a defined syndrome with confidence, and not clear enough to dismiss the concern out of hand. Treating it as either definitely-real or definitely-myth misrepresents where the science actually is.

Mood is a specific thread worth pulling out. There have been reports of low mood and, less commonly, suicidal thoughts associated with finasteride. The causal picture is debated, but the practical implication is not: new or worsening mood changes while taking it are a reason to seek prompt medical review rather than to wait and see.

The regulator's view, and the alert card

In the UK, the MHRA reviewed finasteride following continued reports of psychiatric and sexual side effects. The outcome was not to withdraw the drug — its benefits in appropriate use were judged to outweigh its risks — but to strengthen the warnings and, importantly, to introduce a patient alert card to be provided with the medicine. The card highlights the possibility of mood changes and sexual side effects, and advises stopping and seeking medical advice if mood symptoms develop.

That response is itself informative. A regulator that neither banned the drug nor waved the concerns away is signalling exactly the balanced position this article is trying to describe: a treatment that works, with side effects that are usually uncommon and reversible, but with a tail of reports serious enough to warrant clear warnings and active patient information.

A point that matters for households

Finasteride affects the hormonal pathway involved in the development of male genitalia, which makes it relevant to pregnancy even though the people prescribed it for hair loss are men. Women who are or may become pregnant should not handle crushed or broken tablets, because of a theoretical risk to a developing male foetus. It's a small, specific precaution, easily managed once known — but it's the kind of detail that belongs in a proper prescribing conversation rather than a checkout page.

Practical takeaways

• Finasteride works by lowering DHT, the androgen that drives pattern hair loss; it mainly slows or halts loss, and its effect depends on continued use.
• The efficacy evidence is reasonably good, but the benefit is gradual and maintenance-dependent, not a one-off fix.
• Sexual side effects occur in a minority and are usually reversible; the question of rarer persistent symptoms ("post-finasteride syndrome") is genuinely unresolved and deserves neither dismissal nor amplification.
• The MHRA strengthened its warnings and introduced a patient alert card flagging mood and sexual effects — new mood changes warrant prompt medical review.
• It is a prescription-only medicine, and whether it suits a particular person is a decision for a prescriber who knows their full history.

What this doesn't mean

A balanced account is not a verdict. Describing the side-effect debate evenhandedly doesn't mean the risks are negligible, and explaining that the drug works doesn't mean it's right for everyone. Nothing here is a recommendation to start, continue or avoid finasteride — that judgement depends on an individual's priorities, history and tolerance of uncertainty, weighed with a clinician.

When to seek medical advice

Anyone considering finasteride should have that conversation with a prescriber rather than relying on an online questionnaire alone. If you are already taking it and develop new or worsening low mood, anxiety, suicidal thoughts, or sexual side effects that concern you, seek medical advice promptly. If you've had thoughts of harming yourself, treat that as urgent and contact your GP, NHS 111, or emergency services.

A closing thought

Finasteride is a useful test of whether health writing can be honest. The lazy versions are easy: it's a miracle, or it's a menace. The accurate version is more demanding and less shareable — an effective drug, with mostly modest and reversible side effects, trailed by a minority of serious and incompletely understood reports, regulated by a body that took those reports seriously without panicking. Holding all of that at once is uncomfortable. It's also the only fair way to describe it.

Further reading and sources

• MHRA — Drug Safety Update and patient safety information on finasteride, including the patient alert card
• BNF — finasteride (indications, cautions, and adverse effects)
• NICE Clinical Knowledge Summaries — Hair loss in adults / androgenetic alopecia
• British Association of Dermatologists — patient information on androgenetic alopecia and its treatment

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.